Industry News (HCV)

Hepatitis C Drug Patent Infringements Result in Suit

Published in Hepatitis Weekly, September 21st, 1998

Chiron Corporation announced that it has filed suit against Eli Lilly, Vertex Pharmaceuticals, Gilead Sciences, and Agouron in the United States District Court for the Northern District of California for infringement of U.S. Patent Nos. 5,371,017, 5,585,258, and 5,597,691.

The named companies are among several currently engaged in programs for the development of hepatitis C virus (HCV) protease inhibitor drugs which fall within the scope of Chiron's HCV protease patents, according to Chiron.

Chiron said it has continued to make its patent estate available to companies working to discover drugs for the treatment of HCV infection while at the same time...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1998-09-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry